What happens after I am treated with TILs?
If the therapy works correctly, the patient will not have to be treated with TILs again. However, if the patient has a relapse, a biopsy of the new tumour must be performed. This is because the mutations (genetic changes) in this new tumour will produce different lymphocytes to those of the first treatment. However, recurrences are currently seen in very few cases.
What are potential complications?
Immune-related adverse effects: TIL therapy can cause alterations of the immune system, since a high number of T lymphocytes with PD1 expression are administered.
Secondary tumours.
Autoimmune reactions.
Metallic taste, nausea, vomiting.
Allergic reactions to gentamicin in some patients.
Infusion reaction resulting from administration of a blood product: fever, shivering, skin rash.
Tumour lysis syndrome: kidney failure and dyselectrolytaemia (imbalance in levels of sodium and potassium, among others, in the blood).
Cytokine release syndrome: including fever, nausea and many other side effects.
Substantiated information by:
Published: 21 September 2023
Updated: 21 September 2023
Subscribe
Receive the latest updates related to this content.
Thank you for subscribing!
If this is the first time you subscribe you will receive a confirmation email, check your inbox
